

May 5, 2022

IMMUNOLOGY

Cyclic Citrullinated Peptide Antibody (CCP)**Date effective:** June 2, 2022**Clinical Practice Change:**

The Shared Health Immunology Laboratory at St Boniface Hospital will be changing its testing methodology from the current BioPlex multiplex method to an ELISA method for CCP IgG.

Background Information:

Antibodies against cyclic citrullinated peptide support the diagnosis of rheumatoid arthritis. The sensitivity and specificity of the ELISA method for rheumatoid arthritis are 78.5% and 98.2% respectively as per the vendor EUROIMMUN.

References/Resources:

Test: [Laboratory Information Manual - CCP](#)
Delphic Code: CCP
Sample: Serum 1.0 ml
Normal Range: 0 - 5 RU/ml
Availability: Weekdays (5-7day TAT)
Requisition: [Immunology Autoimmune Laboratory Requisition](#)

Patient Impact:

- As no international reference serum exists for antibodies against cyclic citrullinated peptide, the calibration and reporting is in relative units (RU/ml). There is no linear correlation between the multiplex and ELISA methods. Any patients being followed for treatment response or to monitor disease activity should have baseline data reevaluated.

Contact Information:

- Dr. Ping Sun, Hematopathologist, Medical Director Hematology & Immunology, Shared Health Manitoba, (phone: 204-787-4682) psun@sharedhealthmb.ca
- Jason Warren, Immunology Technical Manager, Shared Health Manitoba, (phone: 204-471-0370) jwarren3@sharedhealthmb.ca